Status:
UNKNOWN
Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study
Lead Sponsor:
Sun Yat-sen University
Collaborating Sponsors:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To explore the progression-free survival rate (progression-free survival, PFS), overall survival (OS), objective response rate(objective response rate, ORR) and safety of patients with Sintilimab + GP...
Eligibility Criteria
Inclusion
- Pathologically diagnosed nasopharyngeal cancer with distant metastasis; not received anticancer treatment.
- ECOG Score (PS score) 0 or 1.
- Neutrophil count \> 1.5\*10\^9/L, hemoglobin \> 90g/L, and platelet count \> 100\*10\^9/L.
- ALT or AST level \< 2.5 times upper normal limit (upper limit of normal, ULN), bilirubin level \< 1.5 times ULN.
- Creatinine clearance level \> 60 ml/min.
- Patients must sign an informed consent and must be willing and able to comply with the visit, treatment protocol, laboratory tests and other requirements specified in the study protocol.
- Pregnant female subjects must agree to use reliable contraception within 1 year from the screening visit to the last Sintilimab administration.
Exclusion
- Age\> 65 years old or \<18 years old.
- HBsAg positive and HBV DNA\> 10\*10\^3 copy number/ml.
- HCV antibody positive.
- Active, known, or suspected autoimmune diseases. Subjects with type I diabetes, hypothyroidism with only hormone replacement therapy, and skin disease without systemic treatment (such as vitiligo, psoriasis, or alopecia) can be selected.
- A history of interstitial lung disease.
- Received systemic hormone or other immunosuppressive therapy with an equivalent dose of\> 10mg of prednisone per day within 28 days prior to signing the informed consent. Subjects with a systemic hormone dose of 10mg prednisone per day or inhaled / topical corticosteroids may be enrolled.
- Received or will be vaccinated within 30 days before signing the informed consent.
- Pregnancy or breastfeeding women (pregnancy tests should be considered).
- Other malignancies within 5 years, except carcinoma in situ, fully treated non-melanoma skin cancer, and papillary thyroid carcinoma.
- previous allergies to macromolecular protein preparations, or any component of Sintilimab.
- Human immunodeficiency virus (HIV) infection.
- Other conditions that may affect the safety or trial compliance of the subject, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic treatment, mental illness or family and social factors.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT05417139
Start Date
July 1 2022
End Date
July 1 2025
Last Update
June 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060